Bifogade filer
Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Abliva AB via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
2023-02-24 08:30:00
A successful financing enabled the start of the FALCON study with KL1333
2022 Summary
Important events during 2022
- In June, Abliva conducted a directed issue of approximately SEK 150 million to several life science specialist and institutional investors and a preferential rights issue of approximately SEK 50 million. In total, the company received approximately SEK 180 million after issue costs.
- In December, Abliva initiated the company’s global, potentially registrational Phase 2 study with KL1333 (the FALCON study) in adult patients suffering from mitochondrial DNA (mtDNA)-related primary mitochondrial diseases.
Important events after the reporting period
- Abliva appointed Dag Nesse as Vice President of Clinical Operations. Mr. Nesse has joined the company’s management team.
- The U.S. Patent and Trademark Office granted a composition of matter patent for the NV354 compound.
- Abliva’s Nomination Committee announced it proposes Edwin Moses as a new Board member and incoming Chair of the Board of Directors at upcoming General Meetings.
- Abliva announces notice of Extraordinary General Meeting, to be held on March 8, 2023, at 11 a.m. at Medicon Village, Scheeletorget 1, in Lund, Sweden.
Financial information
October-December 2022*
- Net revenues: SEK 0 (48,000)
- Other operating income: SEK 1,504,000 (126,000)
- Loss before tax: SEK 17,576,000 (36,871,000)
- Loss per share before dilution: SEK 0.02 (0.09)
- Diluted loss per share: SEK 0.02 (0.09)
January-December 2022*
- Net revenues: SEK 31,000 (151,000)
- Other operating income: SEK 1,716,000 (0,000)
- Loss before tax: SEK 85,264,000 (123,494,000)
- Loss per share before dilution: SEK 0.12 (0.33)
- Diluted loss per share: SEK 0.12 (0.33)
* APM Alternative performance measures, see definition on page 20.
The complete Interim report is available for download below and through Abliva's website www.abliva.com.